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The retinoblastoma gene, RB1, is one of the most frequently mutated genes in human cancer. Rb heterozy-
gous mice develop pituitary tumors with 100% incidence, and the E2F transcription factors are required for
this. To assess whether deregulated E2F activity is sufficient to induce pituitary tumors, we generated trans-
genic mice expressing an inducible E2F3 protein in the intermediate lobe of the pituitary gland. We found that
short-term deregulation of E2F activity, similar to the earliest stages of Rb loss, is able to induce abnormal
proliferation of otherwise quiescent melanotrophs. However, while long-term exposure to deregulated E2F
activity results in hyperplasia of the intermediate lobe, it did not lead to tumor formation. In fact, mela-
notrophs become insensitive to sustained E2F stimulation and enter an irreversible senescence-like state.
Thus, although deregulated E2F activity results in hyperproliferation, it is not sufficient to mimic loss of Rb,
sustain proliferation of melanotrophs, and ultimately induce pituitary tumors. Similarly, we found that
primary cells in tissue culture become insensitive to sustained E2F3 activation and undergo premature
senescence in a pRB-, p16Ink4a-, and p19Arf-dependent manner. Thus, we conclude that deregulated E2F
activity is not sufficient to fully mimic loss of Rb due to the engagement of a senescence response.
Deregulation of a functional retinoblastoma protein (pRB)
pathway is a feature of the majority of human cancers (50).
pRB itself is inactivated in approximately 25% of human tu-
mors, whereas other tumors contain alterations in core mem-
bers of the pRB pathway, including overexpression of cyclin
D1 and CDK4 and inactivation of p16INK4A (43).
Ablation of Rb in the mouse leads to embryonic lethality due
to placental and hematopoietic defects (5, 19, 22). Like hu-
mans, mice carrying a single Rb mutant allele are predisposed
to tumors but develop endocrine tumors mainly affecting the
pituitary and the thyroid glands (15). Pituitary tumors arising
in Rb/ mice originate in melanotroph cells of the interme-
diate lobe of the pituitary that have lost the wild-type Rb allele
(33). Indeed, data obtained with both chimeric mice and pitu-
itary-specific Rb knockout mice have shown that loss of Rb is
an essential and limiting step for pituitary tumor development
(28, 49, 51). Interestingly, inactivation of two of the upstream
regulators of the pRB pathway, p18INK4c and p27KIP1, also
results in pituitary tumors, highlighting the central role of pRB
in pituitary homeostasis (11, 13, 21).
Due to the prominent role of RB1 as a tumor suppressor
gene, it is essential to understand how pRB controls cell pro-
liferation. pRB has been reported to interact with many cellu-
lar proteins, among which the best characterized are the E2F
family of transcription factors (53). The E2Fs are key regula-
tors of the G1-S transition, and their activity is required for
normal cell proliferation in mouse primary cells (52). The
ability of pRB to bind E2F is modulated by the phosphoryla-
tion state of pRB, which is controlled by the combined actions
of cyclin-CDK and CDK inhibitors (2). When pRB is bound to
the E2Fs, it regulates their transcriptional activity by blocking
their transactivation properties and by recruiting repressor
complexes to E2F-responsive promoters (2). Phosphorylation
or loss of pRB therefore results in release of active E2Fs and
derepression of E2F target genes.
Several results obtained in tissue culture cells and in mouse
models have suggested that the E2Fs are key targets for pRB.
For example, deletion of E2f1 or E2f3 delays the embryonic
lethality of Rb-deficient embryos (47, 55). Moreover, loss of
E2f1 and E2f3 has been shown to decrease the incidence of
pituitary tumors in Rb/ mice (53, 54). An open question,
however, is whether deregulated E2F activity alone is able to
mimic Rb loss. In tissue culture studies, ectopic E2F (E2F1-3)
expression is sufficient to promote DNA replication in immor-
talized quiescent rodent fibroblasts in the absence of growth
factors (9, 20, 27, 35, 41). However, the overexpression of
the activating E2Fs is not sufficient to induce S phase in
primary mouse embryo fibroblasts (MEFs) or human diploid
fibroblasts with a functional pRB and p53 pathway (24),
while acute loss of pRB induces cell cycle reentry in primary
MEFs (37).
Deregulation of E2F activity has thus far been studied in
vivo mainly in transgenic animals overexpressing E2F1 in tis-
sues where little is known about the effect of Rb loss (6, 17, 34).
E2F1 overexpression in vivo triggers apoptosis in target tissues,
suggesting a strong selection against transgenic expressing cells
(17). However, in certain tissues, such as the skin and the liver,
E2F1 overexpression can also result in tumor formation (6,
34).
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To assess whether increased E2F activity is able to mimic
loss of pRB, we generated mice with deregulated E2F activity
in the same cell type in which Rb loss results in tumorigenesis.
We report here that deregulated E2F activity, similar to Rb
loss, is able to induce proliferation of otherwise quiescent
melanotrophs of the pituitary gland. Early abnormal prolifer-
ating cells in Rb/ mice are the first evidence of malignant
progression. However, the abnormal proliferating cells which
arise due to deregulation of E2F activity do not result in
malignant transformation but instead give rise to a hyperplastic
phenotype. We demonstrate that melanotrophs, when exposed
to continuous E2F deregulation, become insensitive to further
E2F stimulation and ultimately enter an irreversible senes-
cence-like state. Similarly, mouse and human primary cells
show a biphasic response to deregulated E2F activity, respond-
ing to transient E2F deregulation by undergoing unscheduled
proliferation and activating E2F target genes but being re-
fractory to sustained E2F stimulation and ultimately under-
going premature senescence. We have found that senes-
cence induced by sustained E2F3 activity is mediated by pRB,
p19Arf, and p16Ink4a and thus collectively our results show
that upon deregulated E2F activity, sustained abnormal pro-
liferation is prevented by engagement of the senescence
response mediated by the tumor suppressors pRB, p16Ink4a,
and p19Arf.
MATERIALS AND METHODS
Generation of transgenic mice. To generate the proopiomelanocortin
(POMC)-estrogen receptor (ER)-E2F3 transgenic construct, the rat POMC pro-
moter (14) was cloned in the pCI expression vector (Promega) into which the
ER-E2F3 cDNA (48) was subsequently inserted. The POMC-ER-E2F3 fragment
was excised from the parental plasmid and microinjected into the pronucleus of
day 1-fertilized C57BL/6 embryos, and the resulting embryos were transferred
into pseudopregnant foster mice. The resulting litters were screened for the
presence of the transgene by Southern blot analysis with a radiolabeled rat
POMC fragment as a probe.
Histology and immunohistochemical staining of mouse pituitary gland. Pitu-
itaries were obtained from transgenic and wild-type littermates, matched accord-
ing to age, sex, and genetic background (mixed C57/129). Tamoxifen (Sigma) was
injected at a dose of 1 mg/day (in sunflower oil). Tissues were fixed in 4%
paraformaldehyde and embedded in paraffin. Sections were stained with hema-
toxylin and eosin. Primary antibodies used in this study were PCNA (Pharmin-
gen); E2F3 (TFE31; Santa Cruz) (K. Helin, unpublished data); bromodeoxyuri-
dine (Becton Dickinson); p16 (Santa Cruz H-156 and, with similar results, Santa
Cruz M-156); and MCM2 (Santa Cruz N-19). All antibodies were used on
paraffin-embedded sections microwaved (700 W, three times for 5 min) in 0.01
M citrate buffer (pH 6.0) for antigen retrieval. Detection was performed with
the Envision kit (Dako) for mouse monoclonal antibodies and the Vectastain
ABC kit (Vector Laboratories) for rabbit and goat polyclonal antibodies,
according to the manufacturer’s instructions. 4,6-Diamidino-2-phenylindole
(DAPI) staining of pituitaries was performed on rehydrated paraffin sections
for 4 min.
Cell culture and virus-mediated gene transfer. MEFs were harvested from
13.5-day-old embryos. ARF heterozygous mice were mated to generate sibling-
matched embryos. RBloxP/loxP MEFs were derived from homozygous RBloxP/loxP
embryos. MEFs and TIG3-human telomerase reverse transcriptase cells were
cultured in 5% CO2 in Dulbecco’s modified Eagle’s medium supplemented with
10% fetal bovine serum, 50 U of penicillin per ml, 50 g of streptomycin per ml,
and 2 g of L-glutamine per ml. pBabe-ER-E2F3 constructs were described
previously (31, 48). 4-Hydroxy tamoxifen was added to the medium at 300 nM.
Adeno-Cre stocks were purchased from the Gene Transfer core facility of the
University of Iowa College of Medicine; 100 PFU was used per cell. Serial 3T3
cultivation was conducted as previously described (38).
Immunofluorescence. Bromodeoxyuridine assays on MEFs were performed as
previously described (18). Immunofluorescence was performed as previously
described (31, 48). Detection of senescence-associated heterochromatic foci was
performed as previously described (32).
Chromatin immunoprecipitation. Chromatin immunoprecipitations were per-
formed and analyzed essentially as described (12). Briefly, cells were cross-
linked, harvested, and sonicated (average fragment length of 500 to 1,000 bp).
The lysate was precleared and immunoprecipitated with polyclonal antibodies
specific for E2F3 (2 g of sc878, Santa Cruz), pRB (2 g of sc50), or unrelated
Flag antibody (2 g of F3165, Sigma). Immune complexes were recovered with
blocked protein A beads, the beads were washed thoroughly, then the complexes
were eluted, cross-links were reversed, and material was recovered by phenol-
chloroform extraction and ethanol precipitation. DNA was resuspended in 200
l, and 7.5 l was used per quantitative PCR reaction with 200 nM primers in 25
l of SYBR Green reaction mix (Perkin Elmer). Primer sequences are available
upon request.
Real-time quantitative PCR. cDNA was generated by reverse transcription-
PCR with the PE Applied Biosystems TaqMan reverse transcription reagents.
Reactions were determined with the SYBR Green I detection chemistry system
(Applied Biosystems, Foster City, Calif.), with an ABI Prism 7700 sequence
detection system. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
used as a control gene for normalization. The sequences of the primers used are
available upon request.
Western blotting. For Western blotting, pituitary glands isolated from trans-
genic and wild-type mice were lysed in ELB (50 mM HEPES [pH 7.0], 250 mM
NaCl, 0.1% NP-40) buffer. Protein lysates (25 g) were separated on a sodium
dodecyl sulfate–8% polyacrylamide gel and transferred to Immobilon-P (Milli-
pore) by electroblotting. Immunoblotting was performed with the following
antibodies: ER (Santa Cruz MC-20), pRB (Pharmingen G3-245), and p16 (Santa
Cruz sc-1661).
RESULTS
Generation of ER-E2F3 transgenic mouse. To assess wheth-
er deregulated E2F activity is sufficient to mimic Rb loss, we
generated transgenic mice expressing E2F3 in the intermediate
lobe of the pituitary gland. We used E2F3 due to its ability to
induce quiescent cells to enter S phase more efficiently than
other E2Fs and its reduced apoptotic potential (8). Transgenic
mice expressing an inducible ER-E2F3 fusion protein were
constructed (29, 31, 48). This inducible system enables us to
closely mimic the developmental steps of pituitary tumorigen-
esis observed in Rb/ mice and to avoid potential selection
against transgenes during development.
Expression of the ER-E2F3 protein was regulated by the
proopiomelanocortin (POMC) promoter previously shown to
be active in the corticonotroph and melanotroph cells of the
pituitary gland (14, 23, 25). The presence of the transgene in
the founder mouse and in its litter was determined by Southern
blot analysis (Fig. 1A). The expression of ER-E2F3 was con-
firmed by immunoblotting on total pituitary extracts with an
antibody to the estrogen receptor (Fig. 1B) and in situ by
immunohistochemistry (Fig. 1D) with an antibody to E2F3. As
expected, the transgene is expressed almost exclusively in
melanotrophs of the pituitary gland, and by immunohisto-
chemistry analysis, we estimated that more than 50% of the
melanotroph cells in the intermediate lobe express the ER-
E2F3 fusion protein (Fig. 1D and 3B).
To evaluate the level of E2F3 overexpression in the pituitary
gland, we designed PCR primers that recognize both human
and mouse E2F3 cDNA. Using these primers, we estimate that
the level of E2F3 overexpression in the pituitary gland of
transgenic animals is approximately fourfold above the endog-
enous E2f3 levels (Fig. 1C; see Fig. S1 in the supplemental
material). However, this difference is based on the transgene
being expressed in all cells of the pituitary gland. Since this is
not the case, we have estimated that the mean expression of
E2F3 in POMC-expressing cells is approximately 50-fold
higher than nonproliferating POMC-expressing cells (see Fig.
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FIG. 1. POMC ER-E2F3 transgenic mice. (A) Schematic representation and detection of the ER-E2F3 transgenic construct. BglII restriction
sites, the POMC probe, and the 1.6-kb BglII fragment are indicated. By Southern blot analysis, we detected a transgene-specific band (1.6 kb) and
a band corresponding to the endogenous POMC gene, confirming the presence of the transgene in the founder mice (F0) and the F1 litter. (B)
ER-E2F3 expression as determined by immunoblotting on total pituitary lysates with an estrogen receptor (ER)-specific antibody. (C) (Left panel)
Relative expression of E2F3 mRNA in transgenic (dashed bar) and wild-type (black bar) pituitaries. (Right panel) Expression of murine E2f3 in a
wild-type intermediate lobe (black bar) and in intermediate lobe pituitary tumors (ILPT) derived from Rb wild-type and mutant mice. (D)
ER-E2F3 expression in situ. Immunohistochemistry with an antibody specific for human E2F3 on pituitaries derived from wild-type (WT) and
transgenic (Tg) mice treated for 3 days with tamoxifen (TAM). NL, neural lobe; IL, intermediate lobe; AL, anterior lobe. (E) ER-E2F3 is
functional and induces unscheduled proliferation in vivo. PCNA and MCM2 expression and bromodeoxyuridine (BrdU) incorporation measured
by immunohistochemistry in the intermediate lobe of wild-type (WT) animals treated with tamoxifen and transgenic animals (Tg) treated
witheither tamoxifen or sunflower oil as a control .
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S1 in the supplemental material). Importantly, the levels of
E2f3 expression in pituitary tumors derived from pRB het-
erozygous mice are approximately 5-fold higher compared to
what observed in a normal intermediate lobe (Fig. 1C), sug-
gesting that ER-E2F3 is expressed at 10-fold higher levels in
the transgenic mice compared to Rb-null pituitary tumors.
Thus, we have generated transgenic mice expressing ER-E2F3
in cells from which pituitary tumors in Rb heterozygous mice
originate.
ER-E2F3 fusion protein is inducible and functional. To
characterize the functionality of ER-E2F3 in vivo, we treated
3-month-old transgenic animals and control littermate wild-type
animals for 3 days with either tamoxifen or, as a negative control,
the carrier sunflower oil. Subsequently, the expression of the
known E2F targets PCNA and MCM2 was assessed by immuno-
histochemistry. Tamoxifen treatment of transgenic mice leads to
an increase in PCNA and MCM2 levels in more than 50% of the
melanotrophs of the intermediate lobe, which is similar to the
number of ER-E2F3-positive cells (Fig. 1E). In contrast, PCNA
and MCM2 expression was not affected in control animals (Fig.
1E). Hence, we conclude that the transgenic mice express a fully
functional and inducible E2F3 protein.
Ectopic E2F3 induction results in proliferation of quiescent
melanotrophs. Next we assessed whether ectopic E2F3 expres-
sion, like loss of pRB, results in the proliferation of otherwise
quiescent melanotrophs. In agreement with a previous report
(33), we did not detect any proliferating melanotrophs in the
intermediate lobe of 3-month-old wild-type animals (Fig. 1E
and data not shown). Moreover, we did not detect any prolif-
erating melanotrophs in control mice, confirming the tight
regulation of the ER-E2F3 fusion protein (Fig. 1E). Strikingly,
activation of E2F3 induced proliferation in a high fraction of
melanotrophs (14% of bromodeoxyuridine-positive cells after
3 h of labeling) in tamoxifen-treated transgenic mice, while no
proliferation was observed in the controls (Fig. 1E and 3A).
Thus, our data show that deregulation of E2F activity in mela-
notrophs of the intermediate lobe, like pRB loss, triggers un-
scheduled proliferation.
Deregulated E2F activity results in hyperplasia. Loss of the
second Rb allele in the majority of Rb heterozygous mice
(70%) takes place in a discrete number of cells within 2
months of age (33). In order to mimic the timing of the steps
leading to tumorigenesis in the Rb/ mice, we activated E2F3
by daily tamoxifen injections in 2-month-old transgenic mice
(Fig. 2A). Prior to treatment, no morphological differences
were observed in transgenic animals compared to wild-type
animals (Fig. 2B). As controls, wild-type animals treated with
tamoxifen and mice not treated with tamoxifen were included
FIG. 2. Deregulated E2F activity induces hyperplasia. (A) Experi-
mental design. Schematic representation of tumorigenic steps leading
to intermediate lobe tumors in Rb/ mice (upper panel) and the
experimental approach used in this study (lower panel). (B) Activation
of E2F3 results in hyperplasia. Hematoxylin and eosin staining of
wild-type and transgenic pituitaries treated for 0, 1, 3, and 6 months
with daily injections of tamoxifen (TAM). Note the enlargement of the
intermediate lobe in transgenic mice treated for 3 months and 6
months (bar). (C) Relative thickness of the intermediate lobe. The bar
graph indicates the relative thickness of the intermediate lobe upon
tamoxifen treatment for the indicated times in transgenic animals
relative to wild-type animals and the standard deviation of the mean.
For each time point, the thickness of the intermediate lobe was mea-
sured in at least three different sections derived from five mice per
genotype. The difference in size of the intermediate lobe in transgenic
mice compared to wild-type (WT) mice is statistically significant upon
3 and 6 months of tamoxifen (TAM) treatment (Student t test; P 
0.0003 and P  0.00001, respectively) (D) Neoplastic foci in Rb het-
erozygous mice. Pituitaries were stained as indicated for panel B. Note
the appearance of neoplastic foci in 5-month-old mice and the pro-
gression towards tumor development in 8-month-old mice.
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to monitor the potential effects arising from tamoxifen and
the transgene integration site, respectively. A group of age-
matched Rb/ mice were also monitored during the experi-
ment as positive controls.
Mice were injected with tamoxifen until they were 8 months
old, at which age the vast majority of Rb/ mice have devel-
oped intermediate lobe tumors (28). Groups of 10 mice for
each genotype and treatment were sacrificed after 1 month and
3 months of treatment, and 20 mice were analyzed after 6
months of treatment. The pituitaries of wild-type animals, ei-
ther tamoxifen treated or untreated, appeared morphologically
identical at all stages analyzed (data not shown). Thus, at the
dose used in our experiments, tamoxifen treatment does not
affect pituitary homeostasis. In addition, the pituitaries of non-
treated transgenic animals were morphologically indistinguish-
able from the pituitaries of wild-type mice at all stages ana-
lyzed, demonstrating that the activity of the ER-E2F3 fusion
protein is tightly controlled (data not shown).
We did not observe significant differences in survival be-
tween tamoxifen-treated ER-E2F3 transgenic mice and wild-
type mice throughout the course of the experiment (data not
shown). The pituitary glands of the transgenic mice showed an
enlargement of the intermediate lobe after 1 month of treat-
ment compared to control animals (Fig. 2B and C). This dif-
ference in morphology was more evident following 3 months
of treatment in all the intermediate lobes analyzed (Fig. 2B
and C).
Analysis of transgenic animals treated for 6 months further
confirmed the hyperplastic phenotype (Fig. 2B and C). How-
ever, we found no evidence of macroscopic tumors or neoplas-
tic foci in any (0 of 20) of the pituitaries analyzed from the
tamoxifen-treated transgenic mice. Consistent with previous
reports, we observed the first intermediate lobe tumors in
Rb/ animals by 5 months of age (matched control for trans-
genic mice treated for 3 months) (19, 22, 33). Moreover, in all
the 8-month-old Rb/ animals analyzed (matched controls for
transgenic mice treated for 6 months), either macroscopic le-
sions or neoplastic foci were detected (Fig. 2D). These results
strongly suggest that, although deregulation of E2F activity is
sufficient to induce hyperplastic growth, it is not sufficient to
mimic Rb loss leading to pituitary tumorigenesis.
Melanotrophs become refractory towards E2F stimulation.
To investigate why E2F deregulation does not lead to tumor
formation despite being able to induce unscheduled prolifer-
ation ultimately resulting in hyperplastic growth, we analyzed
the effect of E2F3 activation on melanotroph proliferation
throughout the 6 months of treatment. We found no prolifer-
ation in intermediate lobe melanotrophs of wild-type mice by
3 months of age, and moreover, we did not detect any prolif-
erating melanotrophs in control mice, confirming the absence
of side effects of tamoxifen and the tight regulation of the
ER-E2F3 fusion protein (Fig. 3A and data not shown).
In transgenic mice induced with tamoxifen for 1 month we
found a significant fraction of melanotrophs undergoing pro-
liferation (12% bromodeoxyuridine positive after a 3-h pulse-
labeling), while no proliferation was observed in the controls
(Fig. 3A). The total number of bromodeoxyuridine-positive
cells decreased after 3 months of treatment, and by 6 months
of treatment the percentage of bromodeoxyuridine-positive
melanotrophs decreased to less than 1% (Fig. 3A). Impor-
tantly, E2F3 expression levels were unaffected throughout the
period of tamoxifen induction, suggesting that the decrease
in the number of proliferating cells was not due to a selec-
tion against melanotrophs expressing ER-E2F3 (Fig. 3B).
Consistent with this, we detected only very few apopto-
tic melanotrophs (approximately 1%) by terminal deoxynu-
cleotidyltransferase-mediated dUTP-biotin nick end labeling
(TUNEL) staining in treated animals (data not shown). Our
data therefore suggest that melanotrophs become refractory to
sustained deregulated E2F activity.
Sustained E2F activity induces cell cycle arrest. One poten-
tial explanation for the inability of E2F to induce S phase in the
later stages of the experiment could be that melanotrophs of
older mice are less responsive to deregulated E2F activity than
melanotrophs of younger mice. To test this, we induced E2F
activity for 3 days in 9-month-old transgenic mice not previ-
ously exposed to tamoxifen. As controls for these experiments,
we tested whether increased E2F3 activity could induce S
phase in 9-month-old transgenic mice previously induced with
tamoxifen for 6 months and “rested” for 1 month. Strikingly,
deregulated E2F activity induces S-phase progression in
9-month-old transgenic mice not previously treated with
tamoxifen but failed to do the same in transgenic mice
previously induced for 6 months (Fig. 3C and D). Thus, the
inability to respond to E2F stimulation after long-term in-
duction of the transgene is not due to a refractory state of
“aged” melanotrophs but is an event occurring due to pro-
longed exposure to deregulated E2F activity. Moreover,
while induced E2F activity resulted in a robust induction of the
E2F target gene MCM2, in 9-month-old transgenic mice not
previously treated with tamoxifen, it failed to do so in mice
previously exposed to sustained E2F activity (Fig. 3C). These
FIG. 3. Melanotrophs become resistant to sustained increased E2F activity. (A) Decreased proliferation following sustained E2F activation.
Bromodeoxyuridine incorporation measured by immunohistochemistry in the intermediate lobe of wild-type (WT) and transgenic (Tg) animals
treated for the indicated time with daily tamoxifen (TAM) injections. The bar graph indicates the percentage of bromodeoxyuridine-positive
melanotrophs in the intermediate lobe and the standard deviation of the mean. (B) Expression of ER-E2F3 protein is retained in tamoxifen-treated
mice. Immunohistochemistry analysis of ER-E2F3 expression in the intermediate lobe of wild-type (WT) and transgenic (Tg) animals treated for
the indicated times with daily tamoxifen injections. The bar graph indicates the percentage of E2F3-positive melanotrophs in the intermediate lobe
and the standard deviation of the mean. (C) Sustained E2F activity triggers melanotrophs to become refractory to E2F stimulation. From the top:
bromodeoxyuridine incorporation, MCM2 expression, and hematoxylin and eosin staining of melanotrophs after 3 days of tamoxifen treatment of
9-month-old transgenic mice either not previously exposed to tamoxifen (left panel) or treated for 6 months followed by 1 month of withdrawal
(right panel). Note that the hyperplastic morphology of the intermediate lobe (bar) of the long-term-induced transgenic animals does not regress
upon tamoxifen withdrawal (right panel). (D) Percentage of bromodeoxyuridine-positive melanotrophs. Treatment of 9-month-old transgenic
animals leads to the same extent of S-phase induction achieved in 3-month-old transgenic animals (compare second lane from left with last on the
right). Sustained E2F activity prevents S-phase induction in melanotrophs (fourth and sixth lanes from the left).
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data show that melanotrophs become permanently refrac-
tory to further mitogenic stimulation upon sustained E2F
activity and that this correlates with the lack of induction of
E2F target genes. Interestingly, 1 month of withdrawal had no
effect on the morphology of the intermediate lobe of the trans-
genic animals, suggesting that this event is also irreversible
(Fig. 3C).
Deregulated E2F activity results in a biphasic response in
mouse primary cells. To understand if the engagement of a
refractory state observed in vivo is a cell-autonomous response
to deregulated E2F activity, we tested the outcome of transient
and sustained E2F activity in mouse embryo fibroblast (MEFs).
Induction of ER-E2F3 in growing early-passage MEFs re-
sulted in a slight but significant (P  0.005 at 8 h) increase in
bromodeoxyuridine-positive cells within 8 h of induction
(Fig. 4A). Increased E2F activity in proliferating mouse pri-
mary cells therefore promotes S-phase entry. Notably, how-
ever, the ability of E2F3 to induce proliferation is transient,
because the levels of bromodeoxyuridine incorporation re-
turned to the same levels seen in control cells 24 h after in-
duction (Fig. 4A).
Next we monitored the expression of known E2F target
genes and found that, while a transient (4 h) ER-E2F3 induc-
tion resulted in the transcriptional activation of all genes
tested, longer induction (72 h) failed to do the same (Fig. 4B
and data not shown). Importantly, the expression of ER-E2F3
was unaltered throughout the course of the experiment, ex-
cluding that the different response to E2F3 induction was due
to loss of its expression (Fig. 4C). Our data therefore suggest
that mouse primary cells, like melanotrophs, are not growth
stimulated by sustained increased E2F activity.
Prolonged activation of E2F3 precludes the formation of
transcriptionally active E2F3 complexes. As shown in Fig. 5A,
activation of E2F3 in human diploid fibroblasts also led to a
transient induction of E2F target genes. The inability of de-
regulated E2F activity to maintain the activation of E2F target
genes could be due either to the inaccessibility of responsive
promoters to ER-E2F3 binding or to the inability of the chro-
matin-bound E2F to form active transcriptional complexes. To
test this, we performed chromatin immunoprecipitation assays
and found that, although the expression of E2F target genes
was activated only transiently by E2F3 (Fig. 5A), ER-E2F3 was
also significantly enriched on E2F target promoters 72 h after
activation (Fig. 5B). Thus, ER-E2F3 is bound to E2F promot-
ers after sustained activation but does not function as an acti-
vator of transcription.
Since E2F3 forms active repressor complexes when bound to
pRB, we assessed pRB binding to E2F target promoters after
E2F3 activation. Consistent with previous reports (45), we found
very little pRB associated with E2F target promoters in asynchro-
nously growing cells without E2F activation. Surprisingly, pRB
FIG. 4. MEFs exhibit a biphasic response to E2F3 stimulation. (A)
E2F3 induction enhances S-phase entry in cycling MEFs. The percent-
age of MEFs incorporating bromodeoxyuridine upon E2F3 induction
is shown. NI, not infected; ER-E2F3, infected cells not induced;
ER-E2F3  OHT, infected cells induced with 4-hydroxy tamoxifen. (B)
Transient induction of E2F targets upon E2F stimulation. Expression
levels of the E2F targets PCNA, cyclin E1 (CCNE1), and CDC6 upon
E2F3 induction was assessed by quantitative PCR, normalized against
GAPDH, and the not-induced samples (t  0) set as 1.0. (C) Expression
of the ER-E2F3 fusion protein throughout the assay was assessed at the
indicated times, and vinculin was used as a loading control.
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was recruited to promoters following as little as 4 h of E2F3
activation (Fig. 5B), and significantly, this enrichment increased
upon sustained induction of E2F. This could suggest that pRB
forms a repressive complex with E2F3 on the promoters of E2F
target genes, preventing their sustained activation.
Since pRB can recruit inhibitory histone deacetylase activity
to E2F-responsive promoters (44, 46), we analyzed the acety-
lation state of the promoters at various times after 4-hydroxy
tamoxifen treatment. We did not detect any overall change in
the level of acetylation (histone H3) at E2F target promoters
(data not shown), which could reflect that changes on E2F
target promoters occur at the level of a single nucleosome, as
previously described (30), and not at all nucleosomes associ-
ated with promoters. Collectively, our data suggest that the
inability of E2F to sustain the activation of E2F-responsive
genes is not due to a reduced occupancy of E2F-responsive
promoters by E2F3. In contrast, our data suggest either that
E2F is unable to form activator complexes or that it switches to
repressor complexes. Further work is required to uncover the
molecular mechanisms leading to such a switch and will be the
focus of our future analyses.
Sustained E2F activity induces senescence-like features in
vivo. Constitutive expression of E2F1 can trigger senescence-
like features in human diploid fibroblasts (10). Interestingly, it
FIG. 5. pRB is recruited to E2F dependent promoters in response to E2F3 activation. (A) Transient induction of E2F targets upon E2F3
activation. Expression levels of the E2F targets EZH2, CDC2, and cyclin E1 (CCNE1) after E2F3 activation was assessed by quantitative PCR,
normalized against GAPDH, and not induced (t  0) was set as 1.0. (B) ER-E2F3 binds to E2F-responsive promoters and recruits pRB upon
activation. Enrichment, relative to the input, of the EZH2, CDC2, and GAPDH promoters following E2F3, pRB, or Flag chromatin immuno-
precipitation (ChIP) is shown.
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was reported recently that specific heterochromatic structures,
termed senescence-associated heterochromatic foci, form in
cells undergoing “natural” replicative senescence as well as
premature senescence and that the appearance of these struc-
tures correlate with epigenetic silencing of E2F target genes
(32). We therefore hypothesized that cells enter a premature
senescent state when exposed to sustained deregulated E2F
activity, which could explain their refractory response to
growth stimulation and transcriptional activation. Consistent
with this hypothesis, we found that both mouse and human
primary cells enter premature senescence (also called stasis)
when exposed to sustained E2F3 activity and accumulate se-
nescence markers such as senescence-associated beta-galacto-
sidase activity in MEFs, senescence-associated heterochro-
matic foci, and p16Ink4a accumulation in human diploid
fibroblasts (see Fig. S2 in the supplemental material).
Next we tested whether sustained E2F activity resulted in
senescence-like features in vivo. Interestingly, we observed a
substantial change in the nucleoplasmic-cytoplasmic ratio of
melanotrophs in transgenic mice treated with tamoxifen for 6
months. In wild-type animals, as well as transgenics treated for
only a short period, melanotrophs are characterized by small
cytoplasm and large nuclei (Fig. 6A and data not shown). In
contrast, the nucleoplasmic-cytoplasmic ratio becomes smaller
in long-term-treated transgenic melanotrophs (Fig. 6A). Sim-
ilar morphological changes are observed in tissue culture when
cells undergo senescence.
We next tested whether, as observed in human diploid
fibroblasts, senescence-associated heterochromatic foci are
formed in melanotrophs. Interestingly, we detected aberrant
heterochromatic DNA structures in the melanotrophs of trans-
genic mice treated for 6 months which were absent in control
animals (Fig. 6B and C). Moreover, heterochromatic DNA
structures were also detectable in a small proportion of mela-
notrophs derived from transgenic mice treated for 3 months
(Fig. 6B and C). The inverse correlation between the appear-
ance of heterochromatic foci and the ability of melanotrophs
to respond to E2F activity suggests that sustained E2F activity
results in a senescence-like state.
To further substantiate this observation, we used two inde-
pendent markers of senescence, p16Ink4a and p19Arf (26).
p19Arf is highly expressed in the intermediate lobe of induced
transgenic animals, consistent with its being a direct E2F target
(Fig. 6B). We found that the accumulation of p16Ink4a, like
senescence-associated heterochromatic foci, inversely corre-
lates with the ability of melanotrophs to respond to E2F stim-
ulation, strongly suggesting that prolonged E2F stimulation
leads to senescence-like features in vivo. Notably, we did not
detect any of these senescence markers in cells of interme-
diate lobe tumors derived from Rb/ mice (Fig. 6B and C).
E2F-induced senescence is mediated by pRb, p16Ink4a, and
p19Arf. The vast majority of cancers harbor mutations in the
pRB pathway, which result in deregulation of E2F activity.
Since we found that deregulated E2F activity in the presence of
pRb results in a senescence-like state, we reasoned that inac-
tivation of pRb in this context would be sufficient to overcome
this phenotype. Since pRb inactivation in the pituitary gland is,
by itself, sufficient to induce pituitary tumors, we tested this
hypothesis in MEFs derived from embryos containing floxed
Rb alleles (49). As for wild-type MEFs, ER-E2F3 activation in
Rb-LoxP MEFs results in significant inhibition of cell prolif-
eration compared to the controls (not infected or ER-E2F3
infected but not induced) (Fig. 7A). In contrast, acute loss of
pRb (as a consequence of Cre expression) is sufficient to pre-
vent E2F3-induced senescence (Fig. 7A). We therefore con-
clude that deregulation of E2F activity results in pRB-depen-
dent premature senescence.
Additional proteins are likely to be involved in the induction
of senescence upon E2F deregulation. We were particularly
interested in determining the role of the products of the Ink4a
locus, the tumor suppressors p19Arf and p16Ink4a, given their
accumulation in melanotrophs and their role in senescence.
Following ER-E2F3 activation, we found that while wild-type
cells undergo a dramatic cell growth inhibition, p16Ink4a null
cells continue to proliferate despite being partially growth im-
paired with respect to control noninduced cells (Fig. 7B; see
Fig. S3 in the supplemental material). Importantly, wild-type
and p16Ink4a null MEFs express similar levels of ER-E2F3 (see
Fig. S3 in the supplemental material). Moreover, in agreement
with the observation that p16Ink4a is a mediator of the senes-
cence response induced by E2F3, p16Ink4a levels were in-
creased in wild-type cells, and the number of senescence-
associated -galactosidase-positive cells decreased in
p16Ink4a null MEFs after E2F3 activation (see Fig. S3 in the
supplemental material). However, since p16Ink4a loss leads to
only partial rescue of the senescence response, our results
suggest that other genes are involved in E2F3-induced senes-
cence. Consistent with this, activation of E2F3 in ARF null
cells did not lead to premature senescence of the cells (Fig.
7C). Based on these results, we conclude that both the ARF-
p53 pathway and the p16-pRB pathway regulate the induction
of senescence triggered by increased E2F activity.
DISCUSSION
Previous work has shown the requirement for E2F in pheno-
types associated with loss of pRb (53, 54). Here, we have shown
that deregulated E2F activity mimics the earliest stages of pRb
loss by inducing the proliferation of quiescent melanotrophs. In-
creased E2F activity, however, is not sufficient to completely
FIG. 6. Sustained E2F activity induces pRB-dependent senescence-like features. (A) Morphological changes as a consequence of E2F activity.
Hematoxylin- and eosin-stained intermediate lobe of wild-type and transgenic mice treated for 6 months with tamoxifen. Note the increased
nucleoplasmic-cytoplasmic ratio in transgenic animals compared to the wild type. (B) Accumulation of senescence markers upon sustained E2F
activity. Panels show staining of either pituitary gland sections derived from wild-type (WT) and transgenic (Tg) animals or pituitary tumors derived
from Rb/ mice. (Upper panel) Two magnifications of DAPI staining showing the formation of senescence-associated heterochromatic foci
(SAHFs) in the intermediate lobe of transgenic animals upon sustained E2F activity. Note the formation of foci in transgenic animals treated for
6 months. (Lower panels) Immunohistochemistry analysis of p16Ink4a and p19Arf in the intermediate lobe. (C) Percentage of p16Ink4a and
senescence-associated heterochromatic focus-positive melanotrophs in the intermediate lobe of wild-type and transgenic mice treated for the
indicated times with tamoxifen (TAM) and in the intermediate lobe tumor of Rb/ mice.
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mimic pRb loss, since it fails to induce tumors. Our data demon-
strate that melanotrophs become refractory to further prolifera-
tion stimuli and acquire senescence-like features as a result of
sustained E2F activation. Furthermore, we have shown that
MEFs undergo premature senescence in response to increased
E2F activity. The induction of senescence is dependent on pRB
and is mediated by p19Arf and p16Ink4a (Fig. 8).
Sustained E2F activity induces senescence-like features in
vivo. The first detectable phenotype of cells that have lost wild-
type Rb is their ability to proliferate differently from those
retaining a wild-type copy (33). We found that increased E2F
activity, like pRb loss, is able to drive quiescent melanotrophs
into S phase. Thus, deregulated E2F activity is indeed able to
mimic the early consequences of Rb loss. However, the induc-
tion of proliferation due to increased E2F activity results in
hyperplasia of the intermediate lobe followed by a senescence-
like state, whereas pRb-deficient melanotrophs retain their
ability to proliferate and ultimately give rise to highly invasive
tumors. The question is why increased E2F activity does not
lead to tumorigenesis.
FIG. 7. E2F-induced senenescence is dependent on pRB, p16Ink4a
and p19Arf. (A) E2F-induced senescence is pRB dependent. MEFs
were passaged following a 3T3 protocol. Genotypes and treatments of
cells were as follows: uninfected (RBloxP), ER-E2F3 infected (ER-
E2F3, RB loxP), ER-E2F3 infected and induced with tamoxifen (ER-
E2F3, RB loxP:OHT), Adeno-CRE infected (RB lox P: CRE), Adeno-
CRE and ER-E2F3 infected and induced with tamoxifen (ER-E2F3,
RB loxP: OHT and CRE). Tamoxifen administration and Adeno-CRE
infection were performed at passage 5 and passage 6, respectively, as
indicated by the arrows. (Inset) Protein expression levels of pRB in
MEFs of the indicated genotype either infected with Adeno-CRE or
not infected. The expression of vinculin was used as a loading control.
(B) E2F3-induced senescence is partly dependent on p16Ink4a. MEFs
FIG. 8. Model for the biphasic response to E2F deregulation. See
text for discussion of the model.
were passaged following a 3T3 protocol. Genotypes and treatments of
cells were as follows: wild-type, ER-E2F3 infected (ER-E2F3, Ink4/
), wild-type ER-E2F3 infected and induced with tamoxifen (ER-
E2F3, Ink4/:OHT), p16Ink4a null MEFs ER-E2F3 infected (ER-
E2F3, Ink4*/*) p16Ink4a null MEFs ER-E2F3 infected and induced
with tamoxifen (ER-E2F3, Ink4*/*: OHT). Tamoxifen administration
was performed at the indicated passage (arrow). (C) E2F-induced
senescence is ARF dependent. MEFs were passaged following a 3T3
protocol. Genotypes and treatments of cells as follows: wild-type, ER-
E2F3 infected (ER-E2F3, ARF/), wild-type ER-E2F3 infected and
induced with tamoxifen (ER-E2F3, ARF/: OHT), ARF/ MEFs
ER-E2F3 infected (ER-E2F3, ARF/), and ARF/ MEFs ER-
E2F3 infected and induced with tamoxifen (ER-E2F3, ARF/:
OHT). Tamoxifen administration was performed at the indicated pas-
sage (arrow).
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One explanation could be that pRb, in addition to regulating
E2F activity, also promotes differentiation and that increased E2F
activity is unable to induce DNA replication in the differentiated
gland. We excluded this possibility, showing that transient dereg-
ulation of E2F activity is sufficient to induce S phase regardless of
the age of the mice and is therefore able to overcome the inhi-
bition of a fully mature dopaminergic neural network (7, 16,
36). An alternative explanation, which is still to be tested, is
that loss of pRb, unlike E2F deregulation, prevents the
differentiation of certain cell types (e.g., stem cells) and that
only this subpopulation of cells are capable of giving rise to
tumors. A third possibility is that we only expressed E2F3a
in our studies and not E2F3b, which recently was shown to
repress transcription from the ARF promoter (1). This find-
ing might suggest that increased E2F3a activity is unable to
mimic the loss of pRb due to the inability of this protein to
reduce ARF levels. Although we know that loss of ARF in
tissue culture will prevent premature senescence, we do not
believe that the lack of E2F3b mechanistically explains the
lack of tumorigenesis because ectopic expression of E2F3b
would, like that of the other E2Fs containing a transactiva-
tion domain (E2F1 through 2F5), lead to activation of tran-
scription and not repression of transcription.
A fourth possibility, which we currently favor, is that increased
E2F3 activity induces senescence in vivo and that pRB, in addi-
tion to regulating E2F, has an important checkpoint function.
This suggestion is based on the accumulation of senescence-like
features, such as failure to respond to mitogens, senescence-as-
sociated -galactosidase activity, and accumulation of senes-
cence-associated heterochromatic foci induced by E2F3 in pri-
mary cells. Moreover, we also found several senescence-like
features in vivo, such as increased levels of the cell cycle inhibitor
p16Ink4a, morphological alterations, and the formation of
senescence-associated heterochromatic foci. Thus, we pro-
pose that the induction of senescence acts a tumor suppres-
sion mechanism able to restrain the growth of melanotrophs
harboring deregulated E2F activity in the absence of pRB
loss. Indeed, engagement of a senescence response upon
chemotherapeutic treatment has previously been reported
to act as a tumor suppressor mechanism able to block ab-
normal proliferation of mouse lymphomas (39).
E2F target genes do not respond to sustained activation of
E2F. Interestingly, both in vivo and in tissue culture, the pro-
liferation response of cells to deregulated E2F activity corre-
lates with induction of E2F target genes, while senescence
induction correlates with a lack of E2F target genes. Our data
showing that ER-E2F3 is constantly bound to E2F-responsive
promoters demonstrate that it is not altered accessibility of
promoters that determines the refractory state of these genes.
Instead, our results suggest that E2F3 does not sustain the
formation of activating complexes but most likely forms re-
pressing complexes. Interestingly, pRB is recruited to E2F-
responsive promoters upon activation of E2F3. It is somewhat
surprising that recruitment of pRB is seen as early as 4 h after
E2F3 activation, and it is unclear whether this represents a
subset of cells in which the promoters are already repressed or
whether a critical level of pRB is required to initiate repression
of target genes. However, given the established role of pRB in
the active repression of E2F target genes (3), these data sug-
gest that pRB could play a crucial role in switching E2F3
activity from activator to repressor complexes through the re-
cruitment of chromatin modifiers.
pRB and senescence: a feedback mechanism. Sustained
E2F activity leads to increased expression of p16Ink4a and to
senescence-associated heterochromatic focus formation. Since
p19Arf is an E2F-responsive gene, it is also induced by E2F3.
Importantly, increased levels of p16Ink4a and p19Arf trigger a
pRB-dependent G1 arrest, inducing hypophosphorylation of
pRB (40), which are crucial events in senescence (4, 42). Se-
nescence-associated heterochromatic focus formation occurs
in primary cells undergoing “spontaneous” senescence or Ras-
induced premature senescence (32). The appearance of these
structures coincides with the formation of heterochromatin on
E2F-responsive genes, rendering these refractory to increased
E2F activity. Interestingly, the pRB pathway plays a crucial
role in the formation of senescence-associated heterochro-
matic foci, and pRB has been shown to be recruited to E2F
target promoters in senescent cells (32).
Strikingly, loss of pRB is sufficient to bypass the senescence
induced by increased E2F activity, and thus pRB plays a cru-
cial role in the mechanism of growth inhibition triggered by
sustained deregulated E2F activity. Interestingly, we have also
shown that the products of the Ink4a locus, p19Arf and
p16Ink4a, both mediate E2F3-induced senescence, consistent
with the accumulation of these proteins when E2F activity is
increased. Importantly, the increased expression of p16Ink4a
and p19Arf results in the accumulation of hypophosphory-
lated pRB, providing a negative feedback mechanism able to
restrain E2F-induced proliferation.
In summary, we provide evidence for a dual role of pRB in
restricting tumor formation, which is consistent with our pre-
viously published data showing a dual role of pRB in regulating
the G1/S transition (24). First, pRB controls the activity of a
number of cellular proteins, including the E2Fs, by directly
binding to these. Second, if other genetic events should lead to
aberrant activity of proteins associated with pRB (here exem-
plified by increased E2F activity), it exerts a checkpoint mech-
anism, rendering cells senescent.
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